8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
May 4, 2026·SEC
Material company update
Mar 27, 2026·SEC
ADMA Biologics, Inc.(ADMA)Earnings, Financials & Key Ratios
ADMA•NASDAQ
13.9× P/E·Price updated Jun 19, 2026
AboutADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Show more
- Revenue$510M+19.6%
- EBITDA$200M+35.7%
- Net Income$147M-25.7%
- EPS (Diluted)0.60-25.9%
- Gross Margin57.39%+11.5%
- EBITDA Margin39.11%+13.4%
- Operating Margin37.53%+15.1%
- Net Margin28.8%-37.9%
- ROE35.56%-56.4%
ADMA Key Insights
ADMA Biologics, Inc. (ADMA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 32.5%
- ✓Strong 5Y sales CAGR of 64.6%
✗Weaknesses
- ✗Weak momentum: RS Rating 9 (bottom 9%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ADMA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADMA Price & Volume
ADMA Biologics, Inc. (ADMA) stock price & volume — 10-year historical chart
Loading chart...
ADMA Growth Metrics
ADMA Biologics, Inc. (ADMA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years53.17%
5 Years64.6%
3 Years49.05%
TTM10.99%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-20.03%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-20%
Return on Capital
10 Years-28.93%
5 Years8.8%
3 Years28.37%
Last Year38.76%
ADMA Recent Earnings
ADMA Biologics, Inc. (ADMA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.19-1.7%
$0.19
Rev
$114M-18.2%
$140M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.20+8.1%
$0.18
Rev
$139M-0.3%
$140M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.16+0.0%
$0.16
Rev
$134M-4.0%
$140M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.15+7.1%
$0.14
Rev
$122M-6.4%
$130M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.19vs $0.19-1.7% | $114Mvs $140M-18.2% |
| Q1 2026 | Feb 25, 2026 | $0.20vs $0.18+8.1% | $139Mvs $140M-0.3% |
| Q4 2025 | Nov 5, 2025 | $0.16vs $0.16+0.0% | $134Mvs $140M-4.0% |
| Q3 2025 | Aug 6, 2025 | $0.15vs $0.14+7.1% | $122Mvs $130M-6.4% |
Based on last 12 quarters of dataView full earnings history →
ADMA Peer Comparison
ADMA Biologics, Inc. (ADMA) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 GRFS | 6.26B | 7.40 | 11.28 | 0.2% | 5.58% | 5.43% | 1.15 | |
 BIO | 7.63B | 282.44 | 10.13 | 0.65% | 6.52% | 2.4% | 0.21 | |
 PRPH | 355.28K | 0.08 | -0.04 | -35.82% | -339.31% | -157.67% | 2.46 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 CSL | 14.76B | 360.96 | 21.08 | 0.33% | 14.57% | 34.48% | 1.60 | |
 TAK | 48.84B | 15.63 | 39.28 | 4.28% | 4.25% | 2.62% | 0.63 | |
 OCSL | 1.02B | 11.59 | 29.72 | 60.93% | 17.43% | 3.45% | 1.01 | |
 BHVN | 1.44B | 13.57 | -1.98 | -8.66% | 5.36 |
Compare ADMA vs Peers
ADMA Biologics, Inc. (ADMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ADMA Income Statement
ADMA Biologics, Inc. (ADMA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 22.76M | 16.99M | 29.35M | 42.22M | 80.94M | 154.08M | 258.21M | 426.45M | 510.17M | 509.86M |
Revenue Growth % | 113.49% | -25.37% | 72.79% | 43.85% | 91.72% | 90.36% | 67.58% | 65.15% | 19.63% | 10.99% |
Cost of Goods Sold | 29.16M | 42.19M | 39.5M | 61.29M | 79.77M | 118.81M | 169.27M | 206.9M | 217.41M | 197.44M |
COGS % of Revenue | 128.14% | 248.42% | 134.6% | 145.17% | 98.55% | 77.11% | 65.56% | 48.52% | 42.61% | - |
Gross Profit | -6.4M▲ 0% | -25.21M▼ 293.7% | -10.16M▲ 59.7% | -19.07M▼ 87.8% | 1.17M▲ 106.2% | 35.27M▲ 2906.4% | 88.94M▲ 152.2% | 219.55M▲ 146.8% | 292.76M▲ 33.3% | 312.42M▲ 0% |
Gross Margin % | -28.14% | -148.42% | -34.6% | -45.17% | 1.45% | 22.89% | 34.44% | 51.48% | 57.39% | 61.27% |
Gross Profit Growth % | -248.92% | -293.66% | 59.72% | -87.8% | 106.15% | 2906.39% | 152.21% | 146.85% | 33.35% | - |
Operating Expenses | 32.06M | 35.08M | 31.27M | 45.84M | 59.55M | 74.63M | 67.31M | 80.57M | 101.32M | 104.45M |
OpEx % of Revenue | 140.86% | 206.53% | 106.54% | 108.58% | 73.57% | 48.44% | 26.07% | 18.89% | 19.86% | - |
Selling, General & Admin | 18.09M | 22.5M | 25.91M | 35.05M | 42.9M | 52.46M | 59.02M | 74.12M | 91.58M | 95.52M |
SG&A % of Revenue | 79.49% | 132.48% | 88.28% | 83.02% | 53% | 34.05% | 22.86% | 17.38% | 17.95% | - |
Research & Development | 6.23M | 3.93M | 2.34M | 5.91M | 3.65M | 3.61M | 3.3M | 1.81M | 4.76M | 6.53M |
R&D % of Revenue | 27.37% | 23.11% | 7.99% | 13.99% | 4.5% | 2.35% | 1.28% | 0.43% | 0.93% | - |
Other Operating Expenses | -10.14K | -127.12K | 3.01M | 4.89M | 13M | 18.56M | 4.99M | 4.63M | 4.98M | 2.04M |
Operating Income | -39.31M▲ 0% | -60.29M▼ 53.4% | -41.42M▲ 31.3% | -64.91M▼ 56.7% | -58.37M▲ 10.1% | -39.37M▲ 32.6% | 21.63M▲ 155.0% | 138.98M▲ 542.5% | 191.44M▲ 37.7% | 214.84M▲ 0% |
Operating Margin % | -172.71% | -354.95% | -141.14% | -153.75% | -72.12% | -25.55% | 8.38% | 32.59% | 37.53% | 42.14% |
Operating Income Growth % | -126.83% | -53.37% | 31.29% | -56.71% | 10.08% | 32.56% | 154.95% | 542.49% | 37.75% | - |
EBITDA | -38.08M | -56.84M | -38.17M | -60.97M | -52.88M | -32.25M | 29.96M | 147.03M | 199.54M | 220.96M |
EBITDA Margin % | -167.29% | -334.66% | -130.04% | -144.42% | -65.33% | -20.93% | 11.6% | 34.48% | 39.11% | 43.34% |
EBITDA Growth % | -125.82% | -49.29% | 32.86% | -59.76% | 13.28% | 39.01% | 192.91% | 390.68% | 35.72% | 38.15% |
D&A (Non-Cash Add-back) | 1.23M | 3.45M | 3.26M | 3.94M | 5.5M | 7.11M | 8.33M | 8.04M | 8.1M | 6.13M |
EBIT | -40.47M | -60.22M | -39.29M | -63.76M | -58.59M | -46.63M | -3.21M | 139.64M | 189.77M | 154.34M |
Net Interest Income | -3.23M | -5.33M | -8.19M | -11.7M | -13.02M | -19.23M | -23.41M | -11.83M | -5.24M | -1.77M |
Interest Income | 57.23K | 195.4K | 800.78K | 288.13K | 34.53K | 44.83K | 1.62M | 2.1M | 1.87M | 1.26M |
Interest Expense | 3.29M | 5.52M | 8.99M | 11.99M | 13.06M | 19.28M | 25.03M | 13.93M | 7.11M | 3.04M |
Other Income/Expense | -4.45M | -5.45M | -6.85M | -10.83M | -13.27M | -26.54M | -49.87M | -13.27M | -8.79M | -8.5M |
Pretax Income | -43.76M▲ 0% | -65.74M▼ 50.2% | -48.28M▲ 26.6% | -75.75M▼ 56.9% | -71.65M▲ 5.4% | -65.9M▲ 8.0% | -28.24M▲ 57.2% | 125.71M▲ 545.2% | 182.66M▲ 45.3% | 206.33M▲ 0% |
Pretax Margin % | -192.26% | -387.06% | -164.5% | -179.41% | -88.52% | -42.77% | -10.94% | 29.48% | 35.8% | 40.47% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -71.96M | 35.73M | 40.98M |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -57.24% | 19.56% | 19.86% |
Net Income | -43.76M▲ 0% | -65.74M▼ 50.2% | -48.28M▲ 26.6% | -75.75M▼ 56.9% | -71.65M▲ 5.4% | -65.9M▲ 8.0% | -28.24M▲ 57.2% | 197.67M▲ 800.0% | 146.93M▼ 25.7% | 165.35M▲ 0% |
Net Margin % | -192.26% | -387.06% | -164.5% | -179.41% | -88.52% | -42.77% | -10.94% | 46.35% | 28.8% | 32.43% |
Net Income Growth % | -124.23% | -50.24% | 26.56% | -56.9% | 5.41% | 8.02% | 57.15% | 800% | -25.67% | -20.03% |
Net Income (Continuing) | -43.76M | -65.74M | -48.28M | -75.75M | -71.65M | -65.9M | -28.24M | 197.67M | 146.93M | 165.35M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.91▲ 0% | -1.45▲ 24.1% | -1.05▲ 27.6% | -1.02▲ 2.9% | -0.61▲ 40.2% | -0.43▲ 29.5% | -0.13▲ 69.8% | 0.81▲ 723.1% | 0.60▼ 25.9% | 0.69▲ 0% |
EPS Growth % | -18.63% | 24.08% | 27.59% | 2.86% | 40.2% | 29.51% | 69.77% | 723.08% | -25.93% | -20% |
EPS (Basic) | -1.91 | -1.45 | -1.05 | -1.02 | -0.61 | -0.43 | -0.13 | 0.85 | 0.62 | - |
Diluted Shares Outstanding | 22.9M | 45.19M | 54.35M | 86.15M | 139.58M | 197.87M | 223.98M | 243.34M | 244.9M | 239.96M |
Basic Shares Outstanding | 22.9M | 45.19M | 54.35M | 86.15M | 139.58M | 197.87M | 223.98M | 233.08M | 238.3M | 236.07M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ADMA Balance Sheet
ADMA Biologics, Inc. (ADMA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 63.17M | 44.53M | 85.82M | 153.74M | 208.73M | 270.4M | 257.01M | 331.41M | 466.51M | 511.17M |
Cash & Short-Term Investments | 43.11M | 22.75M | 26.75M | 55.92M | 51.09M | 86.52M | 51.35M | 103.15M | 87.63M | 138.15M |
Cash Only | 43.11M | 22.75M | 26.75M | 55.92M | 51.09M | 86.52M | 51.35M | 103.15M | 87.63M | 138.15M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 3.88M | 1.39M | 3.47M | 13.24M | 28.58M | 15.51M | 27.42M | 50M | 158.43M | 135.86M |
Days Sales Outstanding | 62.22 | 29.92 | 43.15 | 114.44 | 128.86 | 36.73 | 38.76 | 42.79 | 113.35 | 96.95 |
Inventory | 12.63M | 18.62M | 53.06M | 81.54M | 124.72M | 163.28M | 172.91M | 170.24M | 206.47M | 222.1M |
Days Inventory Outstanding | 158.05 | 161.04 | 490.29 | 485.56 | 570.69 | 501.6 | 372.83 | 300.32 | 346.63 | 377.44 |
Other Current Assets | 2.05M | 1.77M | 0 | 0 | 0 | 5.09M | 5.33M | 8.03M | 13.99M | 15.06M |
Total Non-Current Assets | 44.85M | 44.35M | 41.27M | 53.93M | 67.52M | 78.06M | 72.17M | 157.27M | 157.73M | 154.01M |
Property, Plant & Equipment | 30.47M | 30.12M | 32.99M | 45.85M | 58.2M | 68.75M | 63.47M | 63.34M | 71.71M | 71.41M |
Fixed Asset Turnover | 0.75x | 0.56x | 0.89x | 0.92x | 1.39x | 2.24x | 4.07x | 6.73x | 7.11x | 7.07x |
Goodwill | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M |
Intangible Assets | 4.85M | 4M | 3.16M | 2.44M | 1.73M | 1.01M | 499K | 460K | 632K | 630K |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 6.01M | 6.7M | 1.6M | 2.11M | 4.07M | 4.77M | 4.67M | 5.66M | 8.6M | 8.47M |
Total Assets | 108.02M▲ 0% | 88.88M▼ 17.7% | 127.09M▲ 43.0% | 207.67M▲ 63.4% | 276.25M▲ 33.0% | 348.46M▲ 26.1% | 329.18M▼ 5.5% | 488.68M▲ 48.5% | 624.24M▲ 27.7% | 665.18M▲ 0% |
Asset Turnover | 0.21x | 0.19x | 0.23x | 0.20x | 0.29x | 0.44x | 0.78x | 0.87x | 0.82x | 0.84x |
Asset Growth % | 356.06% | -17.72% | 43% | 63.41% | 33.02% | 26.14% | -5.53% | 48.45% | 27.74% | 151.96% |
Total Current Liabilities | 9.44M | 9.63M | 14.03M | 19.95M | 30.38M | 39.27M | 49.81M | 55.54M | 69.54M | 73.54M |
Accounts Payable | 5.92M | 5.9M | 9.17M | 11.07M | 12.43M | 13.23M | 15.66M | 20.22M | 22.52M | 20.52M |
Days Payables Outstanding | 74.1 | 51.04 | 84.77 | 65.95 | 56.87 | 40.64 | 33.77 | 35.67 | 37.81 | 44.75 |
Short-Term Debt | 0 | 29.98K | 0 | 0 | 0 | 0 | 0 | 0 | 3.91M | 4.46M |
Deferred Revenue (Current) | 142.83K | 142.83K | 142.83K | 142.83K | 142.83K | 143K | 182K | 143K | 1.41M | 2.92M |
Other Current Liabilities | 0 | -59.97K | 0 | 207.26K | 16.05M | 1.8M | 2.37M | 1.85M | 41.71M | 47.19M |
Current Ratio | 6.69x | 4.63x | 6.12x | 7.71x | 6.87x | 6.89x | 5.16x | 5.97x | 6.71x | 6.95x |
Quick Ratio | 5.35x | 2.69x | 2.34x | 3.62x | 2.77x | 2.73x | 1.69x | 2.90x | 3.74x | 3.93x |
Cash Conversion Cycle | 146.17 | 139.92 | 448.68 | 534.05 | 642.68 | 497.69 | 377.83 | 307.44 | 422.17 | 429.63 |
Total Non-Current Liabilities | 58.25M | 59.48M | 86.87M | 99.48M | 104.7M | 157.22M | 144.17M | 84.12M | 77.38M | 201.32M |
Long-Term Debt | 42.97M | 44.08M | 83.2M | 92.97M | 94.87M | 142.83M | 130.59M | 72.34M | 75.98M | 199.95M |
Capital Lease Obligations | 0 | 119.08K | 1.3M | 4.33M | 7.46M | 10.7M | 9.78M | 8.56M | 0 | 18.7M |
Deferred Tax Liabilities | 0 | -40.53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 12.73M | 12.88M | 106.57K | 54.89K | 397.35K | 1.85M | 2.11M | 1.67M | 1.41M | 1.37M |
Total Liabilities | 67.69M | 69.11M | 100.9M | 119.42M | 135.08M | 196.49M | 193.98M | 139.66M | 146.92M | 274.86M |
Total Debt | 42.97M | 44.22M | 84.73M | 97.67M | 102.92M | 154.44M | 141.42M | 82.12M | 79.89M | 204.41M |
Net Debt | -136.72K | 21.47M | 57.98M | 41.75M | 51.83M | 67.92M | 90.07M | -21.03M | -7.75M | 66.25M |
Debt / Equity | 1.07x | 2.24x | 3.23x | 1.11x | 0.73x | 1.02x | 1.05x | 0.24x | 0.17x | 0.52x |
Debt / EBITDA | - | - | - | - | - | - | 4.72x | 0.56x | 0.40x | 0.93x |
Net Debt / EBITDA | - | - | - | - | - | - | 3.01x | -0.14x | -0.04x | 0.30x |
Interest Coverage | -12.32x | -10.90x | -4.37x | -5.32x | -4.49x | -2.42x | -0.13x | 10.02x | 26.69x | 50.85x |
Total Equity | 40.33M▲ 0% | 19.77M▼ 51.0% | 26.19M▲ 32.5% | 88.25M▲ 236.9% | 141.17M▲ 60.0% | 151.97M▲ 7.7% | 135.21M▼ 11.0% | 349.02M▲ 158.1% | 477.32M▲ 36.8% | 390.32M▲ 0% |
Equity Growth % | 1004.88% | -50.98% | 32.49% | 236.92% | 59.97% | 7.65% | -11.03% | 158.14% | 36.76% | 238.8% |
Book Value per Share | 1.76 | 0.44 | 0.48 | 1.02 | 1.01 | 0.77 | 0.60 | 1.43 | 1.95 | 1.63 |
Total Shareholders' Equity | 40.33M | 19.77M | 26.19M | 88.25M | 141.17M | 151.97M | 135.21M | 349.02M | 477.32M | 390.32M |
Common Stock | 4.53K | 4.63K | 5.93K | 10.49K | 19.58K | 22K | 23K | 24K | 24K | 24K |
Retained Earnings | -150.69M | -216.44M | -264.72M | -340.47M | -412.11M | -478.02M | -506.26M | -308.58M | -161.65M | -116.33M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.29M | -3.42M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ADMA Cash Flow Statement
ADMA Biologics, Inc. (ADMA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -37.27M | -62.68M | -76.19M | -102M | -112.37M | -59.51M | 8.8M | 118.67M | 50.4M | 128.32M |
Operating CF Margin % | -163.76% | -369.02% | -259.61% | -241.6% | -138.82% | -38.62% | 3.41% | 27.83% | 9.88% | - |
Operating CF Growth % | -104.02% | -68.17% | -21.56% | -33.87% | -10.16% | 47.04% | 114.79% | 1248.55% | -57.53% | 266.45% |
Net Income | -43.76M | -65.74M | -48.28M | -75.75M | -71.65M | -65.9M | -28.24M | 197.67M | 146.93M | 165.35M |
Depreciation & Amortization | 2.69M | 3.45M | 3.26M | 3.94M | 5.5M | 7.11M | 8.33M | 8.04M | 8.1M | 7.97M |
Stock-Based Compensation | 1.56M | 0 | 2.65M | 2.86M | 3.49M | 5.21M | 6.19M | 13.62M | 20.03M | 15.4M |
Deferred Taxes | 1.88M | 122.19K | 0 | -910.1K | 220.76K | 0 | 0 | -84.28M | 11.02M | 10.89M |
Other Non-Cash Items | 638.73K | 961.33K | -320.34K | 1.64M | 1.75M | 12.35M | 32.64M | 2.16M | 3.92M | 2.31M |
Working Capital Changes | -282.24K | -3.69M | -33.5M | -33.78M | -51.68M | -18.29M | -10.12M | -18.54M | -139.59M | -73.6M |
Change in Receivables | -2.86M | 2.49M | -2.08M | -9.77M | -15.34M | 13.07M | -11.92M | -22.58M | -108.43M | -36.45M |
Change in Inventory | 589.32K | -5.99M | -34.65M | -28.47M | -43.19M | -38.56M | -9.63M | 2.67M | -36.23M | -49.91M |
Change in Payables | 2.81M | -20.48K | 3.27M | 1.9M | 1.36M | 799.98K | 3.84M | 4.15M | 2.33M | 955K |
Cash from Investing | 15.21M | -2.1M | -3.81M | -12.72M | -13.51M | -13.91M | -4.98M | -8.57M | -21.89M | -14.77M |
Capital Expenditures | -2.68M | -2.1M | -3.81M | -12.73M | -13.51M | -13.91M | -4.77M | -8.23M | -22.57M | -20.47M |
CapEx % of Revenue | 11.76% | 12.34% | 12.99% | 30.14% | 16.69% | 9.03% | 1.85% | 1.93% | 4.42% | 4.01% |
Acquisitions | 12.5M | 0 | 0 | 2K | 0 | 0 | 0 | 0 | 1M | 6M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 12.5M | 0 | 0 | 2K | 0 | 0 | -210K | -349K | -316K | -297K |
Cash from Financing | 60.75M | 42.92M | 80M | 143.9M | 121.05M | 108.85M | -38.99M | -58.3M | -44.02M | -47.02M |
Debt Issued (Net) | 24.98M | -36.28K | 42.47M | 13.52M | -34K | 51.71M | -23.6M | -60M | -3.17M | 121.36M |
Equity Issued (Net) | 39.2M | 42.94M | 48.4M | 131.2M | 121.14M | 64.64M | -1.42M | 7.49M | -28.96M | -158.66M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -1.42M | 0 | -31.94M | -162.13M |
Other Financing | -3.43M | 13.01K | -10.86M | -816.57K | -62K | -7.51M | -13.97M | -5.8M | -11.89M | -9.72M |
Net Change in Cash | 38.69M▲ 0% | -21.85M▼ 156.5% | -2.72K▲ 100.0% | 29.17M▲ 1073674.4% | -4.83M▼ 116.6% | 35.43M▲ 833.3% | -35.17M▼ 199.3% | 51.8M▲ 247.3% | -15.52M▼ 130.0% | 66.53M▲ 0% |
Free Cash Flow | -39.95M▲ 0% | -64.77M▼ 62.1% | -80.01M▼ 23.5% | -114.73M▼ 43.4% | -125.88M▼ 9.7% | -73.42M▲ 41.7% | 3.82M▲ 105.2% | 110.1M▲ 2782.9% | 27.82M▼ 74.7% | 107.9M▲ 0% |
FCF Margin % | -175.51% | -381.36% | -272.6% | -271.74% | -155.52% | -47.65% | 1.48% | 25.82% | 5.45% | 21.16% |
FCF Growth % | -117.79% | -62.15% | -23.51% | -43.4% | -9.72% | 41.68% | 105.2% | 2782.88% | -74.73% | 19.05% |
FCF per Share | -1.74 | -1.43 | -1.47 | -1.33 | -0.90 | -0.37 | 0.02 | 0.45 | 0.11 | 0.45 |
FCF Conversion (FCF/Net Income) | 0.85x | 0.95x | 1.58x | 1.35x | 1.57x | 0.90x | -0.31x | 0.60x | 0.34x | 0.65x |
Interest Paid | 0 | 0 | 8.11M | 0 | 0 | 0 | 18.05M | 10.67M | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.39M | 0 | 0 |
ADMA Key Ratios
ADMA Biologics, Inc. (ADMA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -243.95% | -218.77% | -210.08% | -132.38% | -62.46% | -44.96% | -19.67% | 81.65% | 35.56% | 38.97% |
Return on Invested Capital (ROIC) | -127.95% | -111.05% | -49.55% | -45.47% | -27.11% | -14.3% | 7.29% | 37.68% | 36.01% | 36.39% |
Gross Margin | -28.14% | -148.42% | -34.6% | -45.17% | 1.45% | 22.89% | 34.44% | 51.48% | 57.39% | 61.27% |
Net Margin | -192.26% | -387.06% | -164.5% | -179.41% | -88.52% | -42.77% | -10.94% | 46.35% | 28.8% | 32.43% |
Debt / Equity | 1.07x | 2.24x | 3.23x | 1.11x | 0.73x | 1.02x | 1.05x | 0.24x | 0.17x | 0.52x |
Interest Coverage | -12.32x | -10.90x | -4.37x | -5.32x | -4.49x | -2.42x | -0.13x | 10.02x | 26.69x | 50.85x |
FCF Conversion | 0.85x | 0.95x | 1.58x | 1.35x | 1.57x | 0.90x | -0.31x | 0.60x | 0.34x | 0.65x |
Revenue Growth | 113.49% | -25.37% | 72.79% | 43.85% | 91.72% | 90.36% | 67.58% | 65.15% | 19.63% | 10.99% |
Related:ADMA Dividend History·ADMA Revenue History·ADMA Price History·ADMA P/E History·ADMA Financial Ratios·ADMA Institutional Holders
ADMA SEC Filings & Documents
ADMA Biologics, Inc. (ADMA) SEC filings — annual & quarterly reports (10-K, 10-Q)
ADMA Frequently Asked Questions
ADMA Biologics, Inc. (ADMA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ADMA Biologics, Inc. (ADMA) reported $509.9M in revenue for fiscal year 2025.
ADMA Biologics, Inc. (ADMA) grew revenue by 19.6% over the past year. This is strong growth.
Yes, ADMA Biologics, Inc. (ADMA) is profitable, generating $165.4M in net income for fiscal year 2025 (28.8% net margin).
Dividend & Returns
ADMA Biologics, Inc. (ADMA) has a return on equity (ROE) of 35.6%. This is excellent, indicating efficient use of shareholder capital.
ADMA Biologics, Inc. (ADMA) generated $107.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.